HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
74 hedge funds and large institutions have $69.9M invested in HOOKIPA Pharma in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 27 reducing their positions, and 15 closing their positions.
114% more capital invested
Capital invested by funds: $32.7M → $69.9M (+$37.2M)
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
3% more funds holding
Funds holding: 72 → 74 (+2)
0.67% more ownership
Funds ownership: 5.37% → 6.04% (+0.67%)
24% less call options, than puts
Call options by funds: $326K | Put options by funds: $427K
26% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$9.03M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.96M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.43M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$4.04M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.1M |
| 2 |
Renaissance Technologies
New York
|
-$915K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$776K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$747K |
| 5 |
Millennium Management
New York
|
-$657K |
HOOK Hedge Fund Activity: Q1 2022 in Review
74 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q1 2022, worth a combined $69.9M — up 114% from $32.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new HOOK positions and 15 closed out — a net gain of 2 holders — while 20 added to existing stakes and 27 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $9.03M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.1M sold.
- 74 institutional investors held HOOKIPA Pharma (HOOK) as of Q1 2022, up from 72 in Q4 2021.
- Funds reported $69.9M of HOOKIPA Pharma stock for Q1 2022, up 114% quarter-over-quarter.
- 17 funds opened new HOOKIPA Pharma positions in Q1 2022 and 15 closed out, a net change of +2 holders.
- The largest HOOKIPA Pharma buyer in Q1 2022 was Deep Track Capital, an estimated $9.03M added.
- The largest HOOKIPA Pharma seller in Q1 2022 was Nantahala Capital Management, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2022.